Interestingly, treatment with PYCR1-IN-1 markedly reduced cell proliferation, migration and anchorage-dependent colony formation in two additional lung cancer cell lines, H460 and H358, in response to TLR agonists and EGF (Supplementary Fig. 8a–e, vehicle versus PYCR1-IN-1 in H460 and Supplementary Fig. 9a–e, vehicle versus PYCR1-IN-1 in H358). Here, PYCR1 is linked to lung carcinoma.